Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 4:52 PM
Ignite Modification Date:
2025-12-24 @ 4:52 PM
NCT ID:
NCT03046550
Brief Summary:
This study evaluates the safety and pharmacokinetics of NTM-1634 in healthy subjects.
Detailed Description:
NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies.
This study is a randomized, double-blind, placebo controlled dose escalation study of three dose cohorts. Cohort A: 0.33mg/kg; B: 0.66mg/kg; and C: 1 mg/kg.
Study:
NCT03046550
Study Brief:
Protocol Section:
NCT03046550